L-ASPARAGINASA EFECTOS ADVERSOS PDF

Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.

Author: Nikodal Mauktilar
Country: Grenada
Language: English (Spanish)
Genre: Video
Published (Last): 23 November 2014
Pages: 122
PDF File Size: 4.42 Mb
ePub File Size: 16.19 Mb
ISBN: 197-4-85955-562-1
Downloads: 49226
Price: Free* [*Free Regsitration Required]
Uploader: Gogal

Review by the Competent Authority or Ethics Committee in the country concerned. Subjects are under 18 years old. Subjects must have a serum creatinine level that is? Clear advanced search filters.

Active treatment for graft-versus-host disease 6. Restricciones de tratamientos previos: Relapsed or Refractory Acute Lymphoblastic Leukemia. Date on which this record was first entered in the EudraCT database:.

For these items you should use the filters and l-aspargainasa add them to -lasparaginasa search terms in the text field. Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial.

Subjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment.

  LOESELIA MEXICANA PDF

Trials with results Trials without results Clear advanced search filters. Age 18 years or younger at the time of study treatment initiation. Known allergy to Captisol a cyclodextrin derivative used to solubilize carfilzomib; for a complete listing of Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc.

Asparaginasa inyectable

Karnofsky or Lansky scores? Positive culture for bacteria or efecos within 14 days of the initiation of therapy 7. Adequate liver function, defined as both of the following: The duration of this interval must be approved by the Onyx study medical monitor.

Plans for treatment or care after the subject has ended the participation in the trial if it is different from l-aparaginasa expected normal treatment of that condition. Title of the trial for lay people, in easily understood, i.

Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible. Cancer AND drug name. Phase 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment of children with relapsed or refractory acute lymphoblastic leukemia ALL -To determine the maximum tolerated dose MTD of carfilzomib in combination with induction chemotherapy.

Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: For agents that have known adverse events occurring beyond 7 days after administration, this period l–asparaginasa be extended beyond the time during which adverse events are known to occur.

  IMMANUEL KANT ZUM EWIGEN FRIEDEN RECLAM PDF

EU Clinical Trials Register. How to search [pdf]. Known allergy to any of the drugs used in the study. The trial involves single site in the Member State concerned.

Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy? IMP l-asparatinasa orphan designation in the indication.

Weight Management Health Library, Free Bariatric Surgery Videos, Learn About Food, Nutrion, Diet

Trials with results Trials without results. Pneumonia AND sponsor name. Combination product that includes a device, but does not involve an Advanced Therapy. Both Female Only Male Only. A group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells. Committee on Advanced therapies CAT has issued a classification for this product.

Son aptos los sujetos que hayan sufrido una alergia previa a la asparaginasa PEG pero que puedan recibir Erwinia. Los sujetos deben haber finalizado todo tipo de inmunoterapia activa p. The IMP has been designated in this indication as an orphan drug in the Community.